Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_assertion type Assertion NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_head.
- NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_assertion description "[Standard chemotherapy for adrenocortical cancer currently is under evaluation in the context of the recently completed FIRM-ACT evaluating the combination of mitotane with either streptozocin or etoposide, cisplatin, and doxorubicin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_provenance.
- NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_assertion evidence source_evidence_literature NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_provenance.
- NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_assertion SIO_000772 22170383 NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_provenance.
- NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_assertion wasDerivedFrom befree-20150227 NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_provenance.
- NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_assertion wasGeneratedBy ECO_0000203 NP864358.RAxj9lD5D0sVSEOY3bojBbgxf2YY_hPepXmz-FyCcv3lQ130_provenance.